10-Year Results of a Phase III Randomized Trial of High-Dose Radiotherapy and Risk-Adapted Androgen Deprivation in Localized Prostate Cancer

被引：0
|
作者：
Zapatero, A. [1 ]
Guerrero Grande, A. D. [2 ]
Maldonado, X., Sr. [3 ]
Alvarez, A. [4 ]
San Segundo, C. Gonzalez [4 ]
Cabeza, M. A. [5 ]
Sole, J. M. [6 ]
Pedro Olive, A. [7 ]
Casas Duran, F. [8 ]
Boladeras, A. [9 ]
Martin de Vidales, C. [1 ]
Vazquez de la Torre, M. L. [10 ]
Varas, S. [11 ]
Calvo, F. A. [12 ]
机构：
[1] Hosp Univ Princesa, Madrid, Spain
[2] Hosp Univ Son Espases, Dept Radiat Oncol, Palma de Mallorca, Spain
[3] Hosp Univ Vall dHebron, Barcelona, Spain
[4] Hosp Univ Gregorio Maron, Madrid, Spain
[5] Hosp Univ 12 Octubre, Madrid, Spain
[6] Hosp Gen Cataluna, Barcelona, Spain
[7] Hosp Plato, Barcelona, Spain
[8] Hosp Clin Barcelona, Barcelona, Spain
[9] LHosp, Catalan Inst Oncol, Dept Radiat Oncol, Barcelona, Spain
[10] Hosp Meixoeiro, Vigo, Spain
[11] Apices Data Management & Biostatist Ctr, Madrid, Spain
[12] Hosp Gen Univ Gregorio Maranon, Madrid, Spain
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2021年 / 111卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
149
引用
收藏
页码：S77 / S77
页数：1
相关论文
共 50 条
  • [1] High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial
    Zapatero, Almudena
    Guerrero, Araceli
    Maldonado, Xavier
    Alvarez, Ana
    Gonzalez San-Segundo, Carmen
    Cabeza Rodriguez, Maria Angeles
    Maria Sole, Josep
    Pedro Olive, Agusti
    Casas, Francesc
    Boladeras, Ana
    Martin de Vidales, Carmen
    Vazquez de la Torre, Maria Luisa
    Vara, Susana
    Luis Sanz, Juan
    Calvo, Felipe A.
    LANCET ONCOLOGY, 2022, 23 (05): : 671 - 681
  • [2] Re: High-dose Radiotherapy and Risk-adapted Androgen Deprivation in Localised Prostate Cancer (DART 01/05): 10-Year Results of a Phase 3 Randomised, Controlled Trial
    Bokhorst, Leonard P.
    Heesterman, Berdine L.
    EUROPEAN UROLOGY, 2022, 82 (04) : 441 - 441
  • [3] Risk-adapted androgen deprivation and high-dose conformal radiotherapy
    Zapatero, A.
    Valcarcel, F.
    Calvo, F.
    Algas, R.
    Bejar, A.
    Maldonado, J.
    Villa, S.
    RADIOTHERAPY AND ONCOLOGY, 2006, 81 : S63 - S64
  • [4] Ten Years Results with High-dose Radiotherapy and Risk-adapted Androgen Deprivation in Prostate Cancer: How Curable is T3 Disease?
    Zapatero, A.
    Garcia-Vicente, F.
    Martin de Vidales, C.
    Fernandez, I.
    Cruz Conde, A.
    Martin, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S309 - S310
  • [5] Prognostic value of testosterone castration levels following androgen deprivation and high-dose radiotherapy in localized prostate cancer: Results from a phase III trial
    Zapatero, Almudena
    Alvarez, Ana
    Guerrero, Araceli
    Maldonado, Xavier
    Gonzalez San Segundo, Carmen
    Cabeza, Maria A.
    Martin de Vidales, Carmen
    Sole, Josep M.
    Pedro Olive, Agusti
    Casas, Francesc
    Boladeras, Ana
    Vazquez de la Torre, Maria L.
    Vara, Susana
    Calvo, Felipe A.
    RADIOTHERAPY AND ONCOLOGY, 2021, 160 : 115 - 119
  • [6] 10-year outcomes of risk-adapted radiotherapy defined by multiparametric MRI for prostate cancer
    Duque Santana, V.
    Diaz Gavela, A.
    Recio, M.
    Guerrero, L. L.
    Pena, M.
    Sanchez, S.
    Thuissard, I. J.
    Andreu, C.
    Sanz-Rosa, D.
    Lopez-Campos, F.
    Gomez-Iturriaga, A.
    Molina, Y.
    Del Cerro Penalver, E.
    Counago, F.
    RADIOTHERAPY AND ONCOLOGY, 2023, 182 : S1195 - S1197
  • [7] Short-Term Androgen Deprivation Therapy and High -Dose Radiotherapy in Intermediate- and High -Risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase III Trial
    Demogeot, N.
    Sargos, P.
    Sahki, N.
    Guerif, S.
    De Crevoisier, R.
    Calais, G.
    Hannoun-Levi, J. M.
    Bouche, G.
    Hennequin, C.
    Cretin, J.
    Belkacemi, Y.
    Khalifa, J.
    Azria, D.
    Bauer, N.
    Pommier, P.
    Pommier, P.
    Simon, J. M.
    Leger, C.
    Beckendorf, V.
    Dubray, B. M.
    Supiot, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : S4 - S5
  • [8] Re: Androgen deprivation therapy and radiotherapy in intermediate risk prostate cancer: A randomized phase III trial
    Guler, Ozan Cem
    Onal, Cem
    EUROPEAN JOURNAL OF CANCER, 2022, 167 : 164 - 165
  • [9] Timing of androgen-deprivation therapy and radical radiotherapy in localized prostate cancer: a phase III randomized controlled trial
    Nieder, Carsten
    STRAHLENTHERAPIE UND ONKOLOGIE, 2020, 196 (08) : 738 - 739
  • [10] Duration of androgen deprivation therapy in high risk prostate cancer: Final results of a randomized phase III trial.
    Nabid, Abdenour
    Garant, Marie-Pierre
    Martin, Andre-Guy
    Bahary, Jean-Paul
    Lemaire, Celine
    Vass, Sylvie
    Bahoric, Boris
    Archambault, Robert
    Vincent, Francois
    Bettahar, Redouane
    Carrier, Nathalie
    Duclos, Marie
    Souhami, Luis
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345